[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-227477-105":3,"detail-sidebar-cat-1-en-105":81,"doc-detail-227477-en":127},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-controlled-prospective-real-world-implementation-study-of-a-12-gene-pharmacogenetic-panel","A Controlled Prospective Real-World Implementation Study of a 12-Gene Pharmacogenetic Panel","","A controlled, prospective real-world implementation study evaluated whether pre-emptive pharmacogenetic panel testing can prevent adverse drug reactions. In seven European countries, 6,944 patients receiving a first prescription for a guideline-recommended “index drug” were genotyped for 50 germline variants across 12 genes. The study arm used treatment based on DPWG recommendations after testing, while controls received standard care. Clinicians were supported via site initiation education and online materials.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/template/","Template",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/template/general/","General",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/template/a-controlled-prospective-real-world-implementation-study-of-a-12-gene-pharmacogenetic-panel/227477/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-controlled-prospective-real-world-implementation-study-of-a-12-gene-pharmacogenetic-panel/227477.png","ImageObject",442,249,{"name":42,"@type":43},"Himbo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/vnd.openxmlformats-officedocument.wordprocessingml.document","2026-09-27","2026-09-10",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the primary goal of the study?","Question",{"text":63,"@type":64},"To assess whether pre-emptive genotyping using a 12-gene pharmacogenetic panel can reduce adverse drug reactions in routine clinical practice.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients assigned to study versus control?",{"text":68,"@type":64},"Patients in the study arm received treatment guided by pharmacogenetic test results using DPWG recommendations, while the control arm received standard treatment.",{"name":70,"@type":61,"acceptedAnswer":71},"What testing approach was used?",{"text":72,"@type":64},"Patients were genotyped for 50 germline variants across 12 pharmacogenetic genes using a pre-emptive panel.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},227477,1789009269,{"code":4,"msg":82,"data":83},"success",[84,89,94,99,104,109,114,119,124],{"id":85,"doc_module":22,"doc_module_name":25,"category_name":86,"show_sort_weight":87,"slug":88},11,"Presentations",90,"presentations",{"id":90,"doc_module":22,"doc_module_name":25,"category_name":91,"show_sort_weight":92,"slug":93},12,"Resumes",80,"resumes",{"id":95,"doc_module":22,"doc_module_name":25,"category_name":96,"show_sort_weight":97,"slug":98},14,"Invoices",70,"invoices",{"id":100,"doc_module":22,"doc_module_name":25,"category_name":101,"show_sort_weight":102,"slug":103},15,"Posters",60,"posters",{"id":105,"doc_module":22,"doc_module_name":25,"category_name":106,"show_sort_weight":107,"slug":108},16,"Social Media",50,"social-media",{"id":110,"doc_module":22,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},17,"Forms",40,"forms",{"id":115,"doc_module":22,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},18,"Letters",30,"letters",{"id":120,"doc_module":22,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},21,"Paper Templates",5,"papers-templates",{"id":125,"doc_module":22,"doc_module_name":25,"category_name":29,"show_sort_weight":4,"slug":126},158,"general-158",{"code":4,"msg":82,"data":128},{"doc_id":79,"user_id":129,"nickname":42,"user_avatar":130,"doc_module":22,"category_id":125,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":136,"language":137,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":138,"faqs":139,"seo_title":140,"seo_description":12,"update_tm":80,"read_time":55},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","Title : A controlled prospective real-world implementation study of a 12-gene pharmacogenetic panel to prevent adverse drug reactions in 6,944 patients in seven European countries.\nAuthors: Jesse J Swen, PhD1, Cathelijne H van der Wouden, PhD1*, Lisanne EN Manson, PharmD1*, Heshu Abdullah-Koolmees, PhD2, Kathrin Blagec, PhD3, Tanja Blagus, Bsc4, Stefan Böhringer, PhD1,5 , Prof Anne Cambon-Thomsen, PhD6, Erika Cecchin, PharmD7, Ka-Chun Cheung,  PhD8, Vera HM Deneer, PhD2,9, Mathilde Dupui, PhD10, Prof Magnus Ingelman-Sundberg, PhD11, Siv Jonsson, PhD12, Candace Joefield-Roka, Bsc13, Katja S Just, MD14, Prof Mats O Karlsson, PhD12, Lidija Konta, PhD15, Rudolf Koopmann, PhD15,16, Marjolein Kriek, MD17, Prof Thorsten Lehr, PharmD18, Christina Mitropoulou, PhD19,20, Emmanuelle Rial-Sebbag, PhD21, Victoria Rollinson, PhD22, Matthias Samwald, PhD3, Elke Schaeffeler, PhD23, 24, Maria Skokou, PhD25, Prof Matthias Schwab, MD23,24,26, Prof Daniela Steinberger, MD15,16, Prof Julia C Stingl, MD14, Roman Tremmel, PhD23, Richard M Turner, PhD22, Mandy H van Rhenen, PharmD8, Cristina L Dávila Fajardo, PhD27, Prof Vita Dolžan, MD4, Prof George P Patrinos, PhD20,25,28,29, Prof Munir Pirmohamed, MD22, Prof Gere Sunder-Plassmann, MD13, Prof Giuseppe Toffoli, MD7, Prof Henk-Jan Guchelaar, PharmD1 , on behalf of the Ubiquitous Pharmacogenomics Consortium\n*Contributed equally\nAffiliations:\n1. Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands.\n2. Division Laboratories, Pharmacy and Biomedical Genetics, Hospital Pharmacy\nUniversity Medical Center Utrecht, Utrecht, The Netherlands\n3. Medical University of Vienna, Center for Medical Statistics, Informatics and Intelligent Systems, Institute of Artificial Intelligence, Vienna, Austria.\n4. Pharmacogenetics Laboratory, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.\n5. Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.\n6. CNRS, Center for Epidemiology and Research in POPulation health (CERPOP), Université de Toulouse, Inserm, UPS, Joint Unit 1295, Toulouse, France.\n7. Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy\n8. Medicines Information Centre, Royal Dutch Pharmacists Association (KNMP), The Hague, The Netherlands.\n9. Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands.\n10. Service de pharmacologie médicale et clinique, CEIP-addictovigilance de Toulouse, faculté de médecine, CHU, 31000 Toulouse, France.\n11. Department of Physiology and Pharmacology, Karolinska Institutet, Biomedicum, Stockholm, Sweden\n12. Department of Pharmacy, Uppsala University, Uppsala, Sweden\n13. Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.\n14. Institute of Clinical Pharmacology, University Hospital RWTH Aachen, Aachen, Germany.\n15. Bio.logis digital health GmbH, Frankfurt am Main, Germany.\n16. Diagnosticum Center for Humangenetics, Frankfurt am Main, Germany.\n17. Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.\n18. Clinical Pharmacy, Saarland University, Saarbrücken, Germany.\n19. The Golden Helix Foundation, London, UK\n20. United Arab Emirates University, College of Medicine and Health Sciences, Department of Genetics and Genomics, Al-Ain, Abu Dhabi, United Arab Emirates\n21. UMR Inserm U1027 and Universite de Toulouse III Paul Sabatier, Toulouse, France\n22. Department of Pharmacology and Therapeutics, Wolfson Centre for Personalised Medicine, The University of Liverpool.\n23. Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany\n24. iFIT Cluster of Excellence (EXC2180) “Image Guided and Functionally Instructed Tumor Therapies”, University of Tuebingen, Tuebingen, Germany\n2","cbCaiibEA2FlJ3P9","https://ap.wps.com/l/cbCaiibEA2FlJ3P9","docx",371960,25,"English","# Summary\n## Background\n## Methods","[{\"question\":\"What was the primary goal of the study?\",\"answer\":\"To assess whether pre-emptive genotyping using a 12-gene pharmacogenetic panel can reduce adverse drug reactions in routine clinical practice.\"},{\"question\":\"How were patients assigned to study versus control?\",\"answer\":\"Patients in the study arm received treatment guided by pharmacogenetic test results using DPWG recommendations, while the control arm received standard treatment.\"},{\"question\":\"What testing approach was used?\",\"answer\":\"Patients were genotyped for 50 germline variants across 12 pharmacogenetic genes using a pre-emptive panel.\"}]","A Controlled Prospective Real-World Implementation Study of a 12-Gene Pharmacogenetic Panel | DOCX"]